Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by First Hawaiian Bank

First Hawaiian Bank increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 21.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,639 shares of the biopharmaceutical company's stock after purchasing an additional 644 shares during the period. First Hawaiian Bank's holdings in Regeneron Pharmaceuticals were worth $2,308,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the business. Boston Common Asset Management LLC boosted its position in Regeneron Pharmaceuticals by 25.3% in the 1st quarter. Boston Common Asset Management LLC now owns 27,343 shares of the biopharmaceutical company's stock valued at $17,342,000 after buying an additional 5,525 shares during the period. Adirondack Trust Co. lifted its position in Regeneron Pharmaceuticals by 4.2% during the first quarter. Adirondack Trust Co. now owns 451 shares of the biopharmaceutical company's stock valued at $286,000 after acquiring an additional 18 shares during the last quarter. Jacobs & Co. CA lifted its holdings in shares of Regeneron Pharmaceuticals by 9.3% during the 1st quarter. Jacobs & Co. CA now owns 10,050 shares of the biopharmaceutical company's stock valued at $6,374,000 after purchasing an additional 859 shares during the last quarter. RK Asset Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 25.8% during the 1st quarter. RK Asset Management LLC now owns 12,563 shares of the biopharmaceutical company's stock valued at $7,968,000 after purchasing an additional 2,574 shares during the last quarter. Finally, Centre Asset Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $7,740,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on REGN. Leerink Partnrs upgraded Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th. Royal Bank of Canada lowered shares of Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 price objective for the company. in a research report on Friday. Bank of America decreased their price objective on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a research report on Thursday, April 17th. JPMorgan Chase & Co. decreased their price target on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating for the company in a report on Monday, March 31st. Finally, Leerink Partners raised shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and raised their price target for the stock from $762.00 to $834.00 in a report on Wednesday, February 5th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $874.56.

Regeneron Pharmaceuticals Stock Down 18.5%

REGN traded down $112.15 on Friday, reaching $493.24. The company's stock had a trading volume of 6,307,887 shares, compared to its average volume of 829,463. The stock has a 50 day moving average of $584.25 and a two-hundred day moving average of $667.42. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $53.25 billion, a price-to-earnings ratio of 12.89, a P/E/G ratio of 2.34 and a beta of 0.43. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $485.00 and a fifty-two week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same quarter in the previous year, the company posted $9.55 EPS. The company's quarterly revenue was down 3.7% on a year-over-year basis. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be given a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.71%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.